Skip to content

Trial · Observational

CompletedPhase not statedRegistry data

Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

Short name IASIS

NCTNCT02472782 (opens ClinicalTrials.gov in a new tab)Other id076/AD7592/S1684/6-5-2015
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase not stated
Enrollment
851 participants (actual)
Sponsor
251 Hellenic Air Force & VA General Hospital · Other
Design
Not stated
Countries
1 country

Greece

Start
May 2015
Primary completion
30 Jun 2018
Completion
15 Dec 2018
First posted
16 Jun 2015 (estimated)
Last update posted
10 Jan 2019
Conditions
Osteoporosis, Postmenopausal · Osteoporosis, Steroid Induced

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20152016201720182019
  1. Ph –

    IASIS

    NCT02472782

    May 2015 to 15 Dec 2018

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This is a study aiming to investigate a possible correlation between the parameters affecting the physicians' therapeutic choice with the patients' overall adherence to osteoporosis treatment. Secondary end-points include correlation between the parameters affecting the physicians' therapeutic choice and the patients' quality of life as well as the evaluation of the whole osteoporosis treatment approach of orthopedic surgeons in Greece (diagnostic means, use of diagnostic and treatment guidelines, methodology of follow - up).

Interventions

  • TeriparatideDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Adherence to osteoporosis treatment assessed by medication possession ratio (MPR)

    Time frame · 2 years

    Registry description

    Adherence to osteoporosis treatment assessed by medication possession ratio Adherence to osteoporosis treatment assessed by medication possession ratio (MPR) and correlation with the parameters affecting the physicians' therapeutic choices

Secondary outcomes(1)

  1. Quality of life assessed by EQ5D questionnaire

    Time frame · 2 years

    Registry description

    Quality of life assessed by EQ5D questionnaire and correlation with the parameters affecting the physicians' therapeutic choice

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

2 studies on this page

PubMed tag: none · 2009

2 results

Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.

Briot et al. 2009Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAcited by 40

PMID 18661089DOI 10.1007/s00198-008-0698-8PUB-18661089

Full text at the publisher2 results
Publisher pageSee results (2)

PubMed tag: none · 2006

3 results

Persistence with teriparatide in patients with osteoporosis: the UK experience.

Arden et al. 2006Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAcited by 50

PMID 16823543DOI 10.1007/s00198-006-0171-5PUB-16823543

Full text at the publisher3 results
Publisher pageSee results (3)

Eligibility

Who could join, as posted.

Sex
All
Age
from 35 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Female patients with postmenopausal osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study. * Male patients ≥ 50 years old with idiopathic osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study. * Male and female patients with steroid-induced osteoporosis (T-score ≤-2,5 SD at any skeletal site) under osteoporosis treatment (except teriparatide) for at least one year with a history of ≥ low-energy fracture during the last 10 years prior the study. Exclusion Criteria: * Prior use of teriparatide or PTH(1-84) * Hypersensitivity to teriparatide regimen. * Pregnancy and lactation. * Hypercalcamia. * Renal deficiency (eGFR \< 30 ml/min). * Other bone metabolic diseases (including hyperparathyroidism and Paget's disease) except primary osteoporosis or steroid induced osteoporosis . * Uninterpretable increases of alkaline phosphatase (ALP) * Prior skeletal radiotherapy. * Skeletal malignancies or bone metastases

PepBank is a research reference. Talk to a doctor before you use any peptide.